You are here: Industry Insights > AstraZeneca

News List

AstraZeneca and Ionis Sign Deal to Develop and Commercialize Eplontersen AmericanPharmaceuticalReview
December 09, 2021
AstraZeneca has entered into a new global development and commercialization agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX.
AstraZeneca and Ionis partner to develop antisense therapy eplontersen Pharmaceutical-Technology
December 09, 2021
AstraZeneca and Ionis Pharmaceuticals have signed an agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX.
Ionis, AstraZeneca Partner to Develop and Commercialize Eplontersen contractpharma
December 08, 2021
Will develop a global strategy for developing, manufacturing and commercializing eplontersen, an antisense medicine to treat transthyretin amyloidosis.
NewsPoints AstraZeneca has higher efficacy with Medigen: study FirstWordPharma
December 06, 2021
Researchers running a trial in Taiwan, China have found that a combination of AstraZeneca's COVID-19 vaccine and the locally-developed Medigen shot is more effective than two doses of AstraZeneca, reported Taipei Times.
Pfizer accused of funding anti-AstraZeneca information FirstWordPharma
December 06, 2021
Pfizer, co-developer of the Comirnaty coronavirus vaccine, has been accused of funding educational presentations that claim AstraZeneca's rival shot was ineffective and even dangerous for some members of the population, reported CityAM.
Possible identification of blood clot trigger for AstraZeneca COVID-19 vaccine PharmaTimes
December 03, 2021
Researchers have identified in those patients experiencing blood clots after vaccination a subsequent condition referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT).
US FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy Pharmaceutical-Business-Review
December 02, 2021
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) to treat BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer patients.
Less Than One Year After Approval, Two Billion Doses of AstraZeneca’s COVID-19 Vaccine Have Been Supplied Globally AmericanPharmaceuticalReview
November 19, 2021
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world WorldPharmaNews
November 17, 2021
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
AstraZeneca to transition to ‘modest profitability’ on future COVID-19 vaccine orders CPhIonline
November 16, 2021
AstraZeneca will start to receive a modest profit from its COVID-19 vaccine as part of a post-pandemic commercial approach, the Anglo-Swedish drugmaker announced at a press conference on Friday.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page